Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale ...

Priyom Bose earned her Ph.D. in Plant Biology and Biotechnology from the University of Madras, India, in 2019 before ...

A win for autoimmune disease, a set back for Alzheimer’s disease, an FDA backing for a multi-cancer blood test, and more led ...

Flow cytometry has evolved from identifying cell populations to highly multiplexed analyses capable of measuring dozens of markers simultaneously. This expansion supports applications ranging from ...

But NRTIs are known to have serious toxicities, so Ambati’s team created new chemical derivatives called kamuvudines that ...

AI has already changed how scientists predict protein structures and design new molecules. The next leap may be discovery itself, with agents that read raw biological data, spot what looks strange, ...

Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.

New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug ...

Injectable peptide drugs have transformed treatment for type 2 diabetes, obesity, cardiovascular disease, and inflammatory conditions, yet their route of administration imposes a daily or weekly ...

Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A, progressively destroys cognitive and motor function in early childhood through a single missing enzyme: ...